Gossamer Bio, Inc. (GOSS )
Currency in USD Disclaimer
Subscribe Now for Delta3 AI Alerts
Don’t miss out on top stock picks and market insights. Subscribe to Delta3 AI Alerts for real-time updates and expert analysis straight to your inbox. Stay informed and maximize your investment potential.
Key Stats
Key stats represent essential financial metrics and indicators used to evaluate a company's performance and potential investment opportunities.
- Symbol GOSS
- Company Gossamer Bio, Inc.
- Price $2.48
- Changes Percentage 18.66
- Change 0.39
- Day Low $2.13
- Day High $2.49
- Year High $3.6
- Year Low $0.66
- Market Cap $563,904,880
- Price Avg 50 EMA (D) $2.58
- Price Avg 200 EMA (D) $1.58
- Exchange NASDAQ
- Volume 7,741,779
- Average Volume 3,824,043
- Open $2.14
- Previous Close $2.09
- EPS -0.61
- PE -4.07
- Earnings Announcement 2025-11-06 20:00:00
- Shares Outstanding $227,381,000
Company brief: GOSSAMER BIO, INC. (GOSS )
- Healthcare
- Biotechnology
- Mr. Faheem Hasnain
- https://www.gossamerbio.com
- US
- N/A
- 02-08-2019
- US38341P1021
Gossamer Bio, Inc., a clinical-stage biopharmaceutical company, focuses on discovering, acquiring, developing, and commercializing therapeutics in the disease areas of immunology, inflammation, and oncology in the United States. The company is developing GB002, an inhaled, small molecule, platelet-derived growth factor receptor, or PDGFR, colonystimulating factor 1 receptor, or CSF1R, and c-KIT inhibitor for the treatment of pulmonary arterial hypertension; GB004, a gut-targeted, oral small molecule for the treatment of inflammatory bowel disease; GB5121, an oral, irreversible, covalent, small molecule inhibitor of Bruton's Tyrosine Kinase for the treatment of primary central nervous system lymphoma; and GB7208, an oral, small molecule, BTK inhibitor for the treatment of multiple sclerosis. It has license agreements with Pulmokine, Inc. to develop and commercialize GB002 and related backup compounds; and Aerpio Pharmaceuticals, Inc. to develop and commercialize GB004 and related compounds. The company was formerly known as FSG, Bio, Inc. and changed its name to Gossamer Bio, Inc. in 2017. Gossamer Bio, Inc. was incorporated in 2015 and is headquartered in San Diego, California.